Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40PJ7 | ISIN: US68232V8845 | Ticker-Symbol: 0T20
NASDAQ
03.07.25 | 15:30
1,470 US-Dollar
+0,68 % +0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRAWS PHARMA INC Chart 1 Jahr
5-Tage-Chart
TRAWS PHARMA INC 5-Tage-Chart

Aktuelle News zur TRAWS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTraws Pharma kündigt Wechsel des Finanzvorstands an1
MoTraws Pharma advances clinical trials for influenza and COVID treatments3
MoTraws Pharma advances antiviral pipeline with multiple regulatory submissions1
MoTraws Pharma, Inc.: Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions227Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting...
► Artikel lesen
MoTraws Pharma, Inc. - 8-K, Current Report1
03.06.Traws Pharma Stock Soars 40% On Positive Clinical Data For Oncology Asset-
03.06.Traws Pharma, Inc.: Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib4
TRAWS PHARMA Aktie jetzt für 0€ handeln
03.06.Traws Pharma, Inc. - 8-K, Current Report-
27.05.Traws Pharma, Inc.: Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness359NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to...
► Artikel lesen
27.05.Traws Pharma, Inc. - 8-K, Current Report6
15.05.Traws Pharma, Inc. - 10-Q, Quarterly Report3
15.05.Traws Pharma, Inc.: Traws Pharma Reports First Quarter 2025 Results and Business Highlights125FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing...
► Artikel lesen
15.05.Traws Pharma, Inc. - 8-K, Current Report2
30.04.Traws Pharma, Inc. - 10-K/A, Annual Report4
18.04.Traws Pharma, Inc. - 8-K, Current Report5
07.04.Traws Pharma, Inc. - 8-K, Current Report1
31.03.Traws Pharma, Inc. - 10-K, Annual Report2
31.03.Traws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business Highlights797Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing...
► Artikel lesen
28.03.Traws Pharma kündigt Ruhestand des CEO und Interimsnachfolger an2
28.03.Traws Pharma CEO Werner Cautreels to retire1
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1